All News
Filter News
Found 3,193 articles
-
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
3/6/2024
GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.
-
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
3/6/2024
Genprex, Inc. today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California.
-
AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's
3/5/2024
AlzeCure Pharma AB announced that another scientific article has been published on the phase I clinical results supporting the continued development of the lead drug candidate NeuroRestore ACD856.
-
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
3/4/2024
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) to UNI-494 for the prevention of Delayed Graft Function (DGF) in kidney transplant patients.
-
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
3/4/2024
Cyprium Therapeutics, Inc. today announced that the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) has awarded a three-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital.
-
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
3/4/2024
GenSight Biologics announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society in Honolulu, Hawaii.
-
Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024
3/4/2024
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.
-
AlzeCure's Alzheimer's Project NeuroRestore ACD856 is Granted an Additional Patent
2/29/2024
AlzeCure Pharma AB announced that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company's clinical drug candidate ACD856, which is being developed against Alzheimer's and other disorders with cognitive impairment.
-
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
2/29/2024
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today presented full clinical results for CNM-Au8® from the VISIONARY-MS Trial long-term open label extension (LTE) in participants with stable relapsing multiple sclerosis (RMS) totaling nearly three years of follow-up at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in West Palm Beach, Florida.
-
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
2/26/2024
Tenaya Therapeutics, Inc. today announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6).
-
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
2/26/2024
Anavex Life Sciences Corp. today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024.
-
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
2/22/2024
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS and multiple sclerosis, reported new, significant survival results from two independent analyses of the pooled data from the intermediate-size EAPs supported by Clene.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update
2/15/2024
POXEL SA announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.
-
Biogen Reaps Rewards of Reata Buyout with EU Approval for Skyclarys in Friedreich’s Ataxia
2/13/2024
Following Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals in July 2023, the drug on Monday was approved in the European Union for treating the rare genetic disorder that causes progressive damage to the nervous system. -
Unravel Initiates RVL-001 Clinical Program in Colombia for Rett Syndrome With Clinical Trial Tool Translation
2/13/2024
Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company to advance drugs for complex diseases, today announced the initiation of a clinical program in Colombia, starting with the translation of the widely-used Rett Syndrome Behavioral Questionnaire (RSBQ) into Spanish under an approved human subject research protocol.
-
Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle
2/8/2024
Vandria SA announced that it has been awarded two grants totalling €3.8M from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively.
-
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
2/7/2024
Genprex, Inc. announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA, and NPRL2, another tumor suppressor gene.
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
2/7/2024
Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2023.
-
AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference
2/6/2024
AlzeCure Pharma AB announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.